Abstract: A device for image capture comprises a memory and one or more processors coupled to the memory and configured to: receive, during a preview mode or a recording, a first image, generate a first saliency map indicative of relative saliency of different regions within the first image, wherein the relative saliency of the different regions is indicative of a likelihood of attracting viewer gaze, generate one or more additional images based on manipulating pixels in the first image, generate one or more additional saliency maps indicative of relative saliency of different regions within the one or more additional images, and determine, during the preview mode or the recording, a camera setting based on the first saliency map and the one or more additional saliency maps.

Abstract: A method includes receiving a series of road images from a side-view camera sensor of the autonomous driving vehicle. For each object from objects captured in the series of road images, a series of bounding boxes in the series of road images is generated, and a direction of travel or stationarity of the object is determined. The methods and apparatus also include determining a speed of each object for which the direction of travel has been determined and determining, based on the directions of travel, speeds, or stationarity of the objects, whether the autonomous driving vehicle can safely move in a predetermined direction. Furthermore, one or more control signals is sent to the autonomous driving vehicle to cause the autonomous driving vehicle to move or to remain stationary based on determining whether the autonomous driving vehicle can safely move in the predetermined direction.

Abstract: The present application provides a novel thyroid hormone ß receptor agonist having better activity, selectivity or safety and represented by formula (I), and use thereof in preventing or treating a disease related to the ß receptor agonist. The disease comprises, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, the liver disease (fatty liver, NASH, NAFLD, etc.), the cardiovascular disease (atherosclerosis, etc.), the thyroid disease (hypothyroidism, thyroid cancer, etc.), etc.

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: A device for image capture comprises a memory and one or more processors coupled to the memory and configured to: receive, during a preview mode or a recording, a first image, generate a first saliency map indicative of relative saliency of different regions within the first image, wherein the relative saliency of the different regions is indicative of a likelihood of attracting viewer gaze, generate one or more additional images based on manipulating pixels in the first image, generate one or more additional saliency maps indicative of relative saliency of different regions within the one or more additional images, and determine, during the preview mode or the recording, a camera setting based on the first saliency map and the one or more additional saliency maps.

Abstract: Provided herein are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: The present invention relates to a steroid compound, a use thereof and a preparation method therefor. It is expected that such compound can effectively treat mental and neurological diseases, and has good active efficacy, pharmacokinetic (PK) performance, oral bioavailability, stability, safety, clearance rate, and/or metabolic performance and the like.

Abstract: Provided herein is compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: Disclosed in the present invention is a cysteine-modified antibody-toxin conjugate. The cysteine-modified antibody-toxin conjugate is characterized in that: the antibody is an antibody in which cysteine is inserted on a fixed point, and insertion sites of the cysteine comprising one or more of the following sites: a 110th site, a IIIth site and a 142th site of a light chain in a Kappa/?L light chain constant region, and a 254th site, a 255th site, a 258th, a 259th site, a 354th site, a 355th site, a 357th site, a 378th site, a 379th site, a 386th site, a 387th site or a 410th site of a heavy chain of a heavy chain constant region of an IgG antibody.

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: The present invention relates to a salt form of (R)—N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in structural formula (I) or a crystal form thereof, and also relates to a method for preparing the salt form of compound I and/or the crystal form thereof, a pharmaceutical composition containing the salt form and/or the crystal form, and the use of same in the preparation of drugs for treating diseases, illnesses or conditions, or a method for treating diseases, illnesses or conditions.

Abstract: The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.

Abstract: The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.

Abstract: The present invention provides a special drug conjugate having a hydrophilic acidic stabilization junction. Compared with a conjugate having a lower drug loading, due to the introduction of the acidic stabilization junction, the conjugate in the present invention can also have a higher drug loading (that is, each targeted reagent has more hydrophilic drug junctions), keeps a desired PK property and has a same or better activity in a body.

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.